Call for Abstract

Annual Conference on Vaccines & Therapeutics STD’s, STI’s & HIV , will be organized around the theme “Current Research Advancements and Challenges in the manufacture and production of HIV Vaccines”

HIV Vaccines 2016 is comprised of 28 tracks and 181 sessions designed to offer comprehensive sessions that address current issues in HIV Vaccines 2016.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 3-1HIV Transmission
  • Track 3-2HIV Transmission rates
  • Track 3-3HIV Transmission risk
  • Track 3-4HIV Transmission statistics
  • Track 4-1Advances in HIV testing
  • Track 4-2HIV Home test
  • Track 4-3HIV Antibody test
  • Track 4-4HIV test Window period
  • Track 5-1Advances in HIV Vaccine
  • Track 5-2HIV Vaccination
  • Track 5-3Hiv vaccine Production
  • Track 6-1Recent HIV Vaccine Trials
  • Track 6-2HIV Clinical Trials
  • Track 6-3HIV Vaccine Clinical Trials
  • Track 7-1AIDS Vaccination
  • Track 7-2Advances in AIDS Vaccine
  • Track 8-1HIV saliva transmit

Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier. Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.

Researchers are working on both bacterial and viral-based recombinant vector vaccines for HIV, rabies, and measles.

  • Track 10-1Attenuated Viruses Used- Response and stimulation
  • Track 10-2New techniques
  • Track 10-3Vectors
  • Track 10-4Recombinant coccidia antigen vaccination
  • Track 10-5Others

A therapeutic HIV vaccine (also known as a treatment vaccine) is a vaccine used in the treatment of an HIV infected person. Therapeutic HIV vaccines are designed to boost the body's immune response to HIV in order to better control the infection.

All experimental therapeutic HIV vaccines are in very early stages of research, and no therapeutic vaccine is anticipated to be available to the general public for many years, if at all.

  • Track 11-1Working mechanisms
  • Track 11-2Receiving eligibility of subject
  • Track 11-3Therapeutic mechanisms
  • Track 11-4Therapeutic HIV-1 vaccines
  • Track 11-5Therapeutic HIV vaccine trials
  • Track 11-6Others

Preventive HIV vaccines are designed to protect HIV negative people from becoming infected or getting sick. Although there is currently no vaccine to prevent HIV, researchers are developing and testing potential HIV vaccines. The goal is to develop a vaccine that can protect people from HIV infection, or at least lessen the chance of getting HIV or AIDS should a person be exposed to the virus.

  • Track 12-1Working mechanisms
  • Track 12-2Designing
  • Track 12-3Ability of vaccines
  • Track 12-4Receiving eligibility of subjects
  • Track 12-5Hiv vaccines for adults
  • Track 12-6Hiv vaccines for Children
  • Track 12-7Hiv vaccines in Pregnancy
  • Track 12-8H1N1 influenza vaccine in HIV-1-infected adults
  • Track 12-9HIV–HBV vaccine
  • Track 12-10Others
  • Track 12-11Instant HIV test

A subunit vaccine presents an antigen to the immune system without introducing viral particles, whole or otherwise. One method of production involves isolation of a specific protein from a virus and administering this by itself.

Instead of the entire microbe, subunit vaccines include only the antigens that best stimulate the immune system. In some cases, these vaccines use epitopes—the very specific parts of the antigen that antibodies or T cells recognize and bind to. Because subunit vaccines contain only the essential antigens and not all the other molecules that make up the microbe, the chances of adverse reactions to the vaccine are lower.

  • Track 13-1Proteins
  • Track 13-2Immune response
  • Track 13-3Capability in Infection
  • Track 13-4Subunit influenza virus vaccines
  • Track 13-5Subunit antigen vaccination
  • Track 13-6Others

If you have HIV (human immunodeficiency virus) or AIDS (acquired immunodeficiency syndrome), you should take special precautions against other infections, such as the flu. That's because you have a disease that makes it difficult for your immune system to fight them. Vaccines (immunizations) can help your body defend itself against infections. However, if you have HIV/AIDS immunizations may effect you differently than people who don't have HIV/AIDS.

Not all vaccines are safe for people with HIV/AIDS. Vaccines made from live viruses should be avoided because they may cause a mild case of the disease. Live vaccines are a weaker form of the germ that causes a particular disease. People with HIV/AIDS should receive vaccines made from inactivated diseases. Inactivated vaccines don't contain a living germ.

Vaccine Side Effects and HIV/AIDS:

Anyone, regardless of their HIV status, is at risk of side effects associated with vaccines, including:

  • Pain, redness, or swelling at the place where you receive the shot
  • Weakness
  • Fatigue
  • Nausea

HIV is a very complex, highly changeable virus, which makes speedy development of a successful preventive HIV vaccine very difficult, but not impossible.  It also takes many years to conduct the research, including the careful clinical testing that will lead to a safe and effective vaccine.

Researchers from around the world have been working for more than two decades to create a vaccine that will protect people against HIV infection. NIAID supports the HIV Vaccine Trials Network (HVTN), an international collaboration of scientists and educators searching for an effective and safe HIV vaccine.

  • Track 15-1Preclinical HIV Research
  • Track 15-2Modified vaccinia Ankara:Vaccinia virus
  • Track 15-3Translational HIV Vaccine Research
  • Track 15-4Clinical HIV Vaccine Research
  • Track 15-5Preclinical HIV Research
  • Track 15-6NIAID HIV Vaccine Research
  • Track 15-7HIV Vaccine Designs and Strategies
  • Track 15-8Basic HIV Vaccine Discovery
  • Track 15-9HIV Transmission/Diversity
  • Track 15-10Current Advancements
  • Track 15-11Stem cell transplantation
  • Track 15-12Microbicides for sexually transmitted diseases
  • Track 15-13Long-term nonprogressor
  • Track 15-14Age acceleration effects due to HIV infection
  • Track 15-15New developments
  • Track 15-16Updates
  • Track 15-17Support
  • Track 16-1HIV Vaccine Strategies
  • Track 16-2HIV Prevention
  • Track 16-3Hiv-1 vaccine development
  • Track 16-4Hiv vaccine development challenges
  • Track 16-5Current status of hiv vaccine development
  • Track 16-6Current trends in hiv vaccine development
  • Track 16-7Hiv vaccine development from animal models
  • Track 16-8Hiv-1 diversity
  • Track 16-9Antibodies in Hiv-1 vaccine development and therapy
  • Track 16-10Progress in Hiv-1 vaccine development
  • Track 17-1Effect of Vaccines on HIV Disease Progression
  • Track 17-2Safety of Life
  • Track 17-3Attenuated Virus Vaccines in HIV Infection
  • Track 17-4Others
  • Track 18-1Bacterial Diarrhea
  • Track 18-2Bacterial Pneumonia
  • Track 18-3Mycobacterium Avium Complex (MAC)
  • Track 18-4Mycobacterium Kansasii
  • Track 18-5Syphilis & Neurosyphilis
  • Track 18-6Tuberculosis (TB)
  • Track 19-1Aspergillosis
  • Track 19-2Candidiasis (thrush, yeast infection)
  • Track 19-3Coccidioidomycosis
  • Track 19-4Cryptococcal Meningitis
  • Track 19-5Histoplasmosis
  • Track 20-1Anal Dysplasia/Cancer
  • Track 20-2Cervical Dysplasia/Cancer
  • Track 20-3Lymphomas
  • Track 20-4Others
  • Track 21-1Cytomegalovirus (CMV)
  • Track 21-2Cytomegalovirus (CMV)
  • Track 21-3Hepatitis C
  • Track 21-4Herpes Simplex Virus (oral & genital herpes)
  • Track 21-5Herpes Zoster Virus (shingles)
  • Track 21-6Human Papilloma Virus (HPV, genital warts, anal/cervical dysplasia/cancer)
  • Track 21-7Molluscum Contagiosum
  • Track 21-8Oral Hairy Leukoplakia (OHL)
  • Track 21-9Progressive Multifocal Leukoencephalopathy (PML)
  • Track 22-1Cryptosporidiosis
  • Track 22-2Isosporiasis
  • Track 22-3Microsporidiosis
  • Track 22-4Pneumocystis Pneumonia (PCP)
  • Track 22-5Toxoplasmosis
  • Track 23-1AIDS Dementia Complex (ADC)
  • Track 23-2Peripheral Neuropathy
  • Track 23-3Other Conditions and Complications
  • Track 23-4Aphthous Ulcers (Canker Sores)
  • Track 23-5Thrombocytopenia (low platelets)
  • Track 23-6Wasting Syndrome
  • Track 24-1Primary infection
  • Track 24-2Asymptomatic infection
  • Track 24-3Symptomatic infection
  • Track 24-4Health monitoring
  • Track 24-5Monitoring when blood tests are unavailable
  • Track 25-1Pneumococcus
  • Track 25-2Hepatitis B
  • Track 25-3Hepatitis A
  • Track 25-4Influenza
  • Track 25-5Haemophilus influenzae
  • Track 25-6Polio, Diphtheria, Pertussis, and Tetanus
  • Track 25-7Measles, Mumps, Rubella
  • Track 25-8Varicella and Herpes Zoster
  • Track 25-9HPV Vaccination in HIV Infection
  • Track 25-10Others
  • Track 26-1Vaccine Concepts - Protein Immunogens
  • Track 26-2Innate Immunity
  • Track 26-3Mucosal Immunity
  • Track 26-4New Env Immunogens
  • Track 26-5Vaccine Immunogens / Delivery
  • Track 26-6Mucosal Immunology
  • Track 26-7New Concepts in Immune Induction
  • Track 26-8Immunogens and Antigen Processing
  • Track 26-9Humoral Immunity
  • Track 26-10Immunogens and Antigen Processing
  • Track 26-11B Cell Immunology
  • Track 26-12HIV-1 DNA and peptide immunizations
  • Track 26-13Vaccinia virus and protein immunizations for HIV-1 
  • Track 26-14Immunizations in HIV-Infected Patients
  • Track 27-1STDs during Pregnancy
  • Track 27-2STDs & Infertility
  • Track 27-3HIV/AIDS & STDs
  • Track 27-4Gonorrhea
  • Track 27-5Bacterial Vaginosis
  • Track 27-6Hepatitis, herpes, and human papilloma viruses
  • Track 27-7Syphilis, granuloma inguinale and gonorrhea,chancroid and chlamydia
  • Track 27-8Trichomoniasis, candidiasis
  • Track 27-9Mucosal inflammation, protective microbiome and natural barriers to STDs
  • Track 27-10Reverse sequence syphilis testing: Pros and cons of syphilis screening with EIA
  • Track 27-11Other STDs
  • Track 28-1Hepatitis A
  • Track 28-2Hepatitis B
  • Track 28-3Hepatitis C
  • Track 28-4Hepatitis hiv infection
  • Track 28-5Hiv hepatitis vaccine
  • Track 28-6Symptoms of hepatitis hiv
  • Track 28-7Hepatitis c treatment for hiv positive
  • Track 28-8Hepatitis b vaccination for hiv patients
  • Track 28-9Hepatitis e virus in hiv-infected patients
  • Track 28-10Hiv varicella vaccine